NewAmsterdam Pharma Company N.V. (NAMSW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysts estimate Earnings Per Share (EPS) of $-2.03 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.56 vs est $-2.03 (missed -26%). 2025: actual $-1.75 vs est $-1.67 (missed -5.1%). Analyst accuracy: 87%.
EPS Estimates — NAMSW
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.56
vs Est –$2.03
▼ 20.7% off
2025
Actual –$1.75
vs Est –$1.67
▼ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NAMSW
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.046B
vs Est $0.034B
▲ 25.9% off
2025
Actual $0.023B
vs Est $0.024B
▼ 6.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
